Paul Little
Chief Executive Officer Atrogi
Seminars
Thursday 29th October 2026
Targeting B2-Receptors to Develop Obesity Therapeutics That Preserve Muscle Mass
9:30 am
- Stimulating the B2 adrenergic receptor to combat obesity
- Leveraging Atrogi’s GPCR discovery platform to discovery precise targets to manage metabolism
- Highlighting ATR-339 clinical data to demonstrate durable, muscle maintaining therapeutics
Wednesday 28th October 2026
Panel & Audience Discussion: Evaluating Oral, Injectable & DNA Delivery Methods to Align Modality Selection with Clinical Performance & Commercial Scale
4:15 pm
- Comparing modality trade-offs in potency, safety and half-life between oral small molecules and injectable peptide therapeutics to guide smarter development decisions
- Exploring how advances in oral delivery and next-generation formats to expand treatment options beyond injectables
- Discussing the manufacturing strengths and pitfalls of oral, DNA and injectable peptide therapies to align delivery mechanisms with commercial viability and faster routes to market
